Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more
Alkem Laboratories Limited - Asset Resilience Ratio
Alkem Laboratories Limited (ALKEM) has an Asset Resilience Ratio of 31.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Alkem Laboratories Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Alkem Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹15.48 Billion | 7.63% |
| Short-term Investments | ₹49.26 Billion | 24.28% |
| Total Liquid Assets | ₹64.74 Billion | 31.91% |
Asset Resilience Insights
- Very High Liquidity: Alkem Laboratories Limited maintains exceptional liquid asset reserves at 31.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alkem Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Alkem Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Alkem Laboratories Limited (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Alkem Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 24.32% | ₹43.03 Billion | ₹176.91 Billion | -0.17pp |
| 2024-03-31 | 24.49% | ₹38.15 Billion | ₹155.75 Billion | +4.62pp |
| 2023-03-31 | 19.88% | ₹27.34 Billion | ₹137.57 Billion | +2.19pp |
| 2022-03-31 | 17.69% | ₹24.89 Billion | ₹140.69 Billion | +3.89pp |
| 2021-03-31 | 13.79% | ₹15.89 Billion | ₹115.19 Billion | +12.41pp |
| 2020-03-31 | 1.38% | ₹1.38 Billion | ₹99.46 Billion | -2.62pp |
| 2019-03-31 | 4.01% | ₹3.29 Billion | ₹82.08 Billion | +1.66pp |
| 2018-03-31 | 2.34% | ₹1.80 Billion | ₹76.66 Billion | -6.61pp |
| 2017-03-31 | 8.95% | ₹5.88 Billion | ₹65.68 Billion | +3.10pp |
| 2016-03-31 | 5.85% | ₹3.24 Billion | ₹55.35 Billion | -7.98pp |
| 2015-03-31 | 13.83% | ₹7.33 Billion | ₹52.96 Billion | +7.38pp |
| 2014-03-31 | 6.46% | ₹2.81 Billion | ₹43.48 Billion | +4.79pp |
| 2013-03-31 | 1.66% | ₹673.10 Million | ₹40.48 Billion | -41.47pp |
| 2012-03-31 | 43.13% | ₹13.73 Billion | ₹31.82 Billion | +7.85pp |
| 2011-03-31 | 35.28% | ₹9.14 Billion | ₹25.89 Billion | -- |